Evidence map›Paper›PMID 42501387›Full record

ReviewAdvanced materials (Deerfield Beach, Fla.)2026

A Chemical Framework for Engineering Extracellular Vesicles' Biointerface to Advance Precision Therapeutics.

Leila Pourtalebi Jahromi, Felix Geng, Jan-Noël Frenzke, Gregor Fuhrmann

Abstract readReview
In one paragraph

Review in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Leila Pourtalebi JahromiFaculty of Science, Department of Biology, Pharmaceutical Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Felix GengFaculty of Science, Department of Biology, Pharmaceutical Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Jan-Noël FrenzkeFaculty of Science, Department of Biology, Pharmaceutical Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Gregor FuhrmannFaculty of Science, Department of Biology, Pharmaceutical Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID https://orcid.org/0000-0002-6688-5126

Funding

DATIPilot-Sprint-NAVET 03DPS1138AEuropean Research Council 945602German Federal Ministry of Research, Technology, and SpaceNCHHSTP CDC HHS H25 PS001138
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are membrane-bound nanoparticles ubiquitously secreted by all cell types and serve diverse physiological and pathological functions. Due to their pivotal roles in pathophysiological processes and their inherent biomimetic properties, EVs have attracted significant attention as biomarkers, as well as for tissue engineering and drug delivery. The surface chemistry of EVs dictates their interactions with their environment. Great strides have been made to tailor this biochemical interface with the aim of enhancing cargo delivery, target specificity, immune evasion, and tracking capabilities, while preserving EVs' stability and functional integrity. Approaches to surface modification primarily encompass genetic and metabolic manipulation of parent cells, application of physical forces, and chemical reactions. In this manuscript, we introduce a comprehensive chemistry-centric framework for EV surface engineering that integrates demonstrated EV modification strategies with protein- and cell-surface chemistries not yet applied to EVs, delineating their functional scope and translational potential for advancing EV-based therapeutics.

Indexed as

Extracellular VesiclesPrecision MedicineAnimalsHumansSurface Propertiesbioengineeringbioorthogonal chemistrychemical biologyextracellular vesiclessurface engineering

Identifiers

PMID42501387
PMCPMC13579185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.